{"id":"W4405096070","doi":"10.1182/blood-2024-203060","title":"PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Tolerability; Protein arginine methyltransferase 5; Medicine; Hematologic Neoplasms; Refractory (planetary science); Internal medicine; Phases of clinical research; Methyltransferase; Pharmacology; Oncology; Adverse effect; Clinical trial; Chemistry; Transplantation; Methylation; Biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001812507,0.00116438,0.001286908,0.0003706752,0.0003615844,0.0007550382,0.001048562,0.0008427688,0.005140048],"category_scores_gemma":[0.0009328333,0.0005029564,0.0008666113,0.0002822094,0.0009090521,0.0007883924,0.0005875466,0.00224356,0.00084255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007571591,"about_ca_system_score_gemma":0.001626495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005700247,"about_ca_topic_score_gemma":0.00211988,"domain_scores_codex":[0.9995654,0.0002034744,0.00001756164,0.00009642638,0.00004301914,0.0000741812],"domain_scores_gemma":[0.9991302,0.0001028654,0.0001902719,0.00008677744,0.00005685557,0.0004330402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6619847,0.08045175,0.0173425,0.001214425,0.001849889,0.0003174437,0.0003908897,0.002533088,0.09172682,0.0006342921,0.006406148,0.1351479],"study_design_scores_gemma":[0.4540119,0.5169954,0.01539177,0.0000454598,0.0006471968,0.0003893488,0.00006960211,0.001091198,0.006364858,0.0003797029,0.004585987,0.00002748403],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888968,0.001577804,0.001136802,0.0004157828,0.00009248702,0.004296079,0.00146935,0.000227717,0.001887114],"genre_scores_gemma":[0.9822893,0.000870074,0.004990774,0.001136486,0.0001274318,0.004647115,0.002698959,0.00004947486,0.003190457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005140048,"threshold_uncertainty_score":0.01719511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01645209202164249,"score_gpt":0.2911731206852303,"score_spread":0.2747210286635878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}